Enzymotec (NASDAQ:ENZY) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, January 6th.
ENZY has been the topic of a number of other reports. Zacks Investment Research upgraded Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Jefferies Group restated a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research note on Thursday, October 19th. Finally, Wells Fargo & Co lifted their price objective on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $11.75.
Enzymotec (NASDAQ:ENZY) remained flat at $$11.85 during mid-day trading on Friday. The firm has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a P/E/G ratio of 3.19 and a beta of 1.22. Enzymotec has a 1 year low of $6.30 and a 1 year high of $12.35.
A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new position in Enzymotec during the third quarter worth about $107,000. Osborn Williams & Donohoe LLC acquired a new position in Enzymotec during the third quarter worth about $137,000. State Street Corp grew its holdings in Enzymotec by 1.8% during the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 380 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in Enzymotec in the 2nd quarter worth about $2,350,000. 15.73% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/enzymotec-enzy-lowered-to-sell-at-bidaskclub.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.